Aspergillus fumigatus Volatile Secondary Metabolite Dynamics for the Identification of Azole-resistant Aspergillosis
烟曲霉挥发性次生代谢动态用于鉴定唑类抗性曲霉病
基本信息
- 批准号:9299327
- 负责人:
- 金额:$ 25.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-03-01 至 2019-02-28
- 项目状态:已结题
- 来源:
- 关键词:AgricultureAllergic Bronchopulmonary AspergillosisAnabolismAntifungal AgentsAntifungal TherapyAsiaAspergillosisAspergillusAspergillus fumigatusAttenuatedAzole resistanceAzolesBiological AssayBreath TestsBreathingCell DeathCessation of lifeChronicClinicalConsensusCytochrome P450DataDetectionDevelopmentDiagnostic ProcedureDiagnostic testsEarly identificationEnvironmentErgosterolEuropeExplosionFailureFungal Drug ResistanceGas ChromatographyGeographic DistributionGrowthGuidelinesImmune systemImmunocompromised HostIn VitroIncidenceIndustrial fungicideInfectionItraconazoleLanosterolLungMedicalMetabolicMethodsModelingMorbidity - disease rateMusMutationNephrotoxicPatientsPharmaceutical PreparationsPhenotypePolyenesReportingResistanceRiskRisk FactorsSesquiterpenesSoilSpectrometryStructureTestingTherapeuticTimeToxic effectTriazolesVoriconazoleWaterWorkattenuationbaseclinical riskexperimental studyfungusin vivomortalitynephrotoxicitynovelpressureresistance mechanismresponsesoil samplingtandem mass spectrometry
项目摘要
Project Summary/Abstract: Invasive aspergillosis (IA) is a leading cause of morbidity and death in
immunocompromised patients, with over 200,000 cases worldwide per year. While advances in diagnostic testing
for IA and the development of potent, less toxic triazole antifungal drugs have reduced IA-associated mortality from
68% to 25%, an alarming rise in the incidence and geographic distribution of azole-resistant Aspergillus fumigatus
(ARAF) over the past decade is steadily offsetting these gains and compromising the use of triazole antifungal drugs
as first-line therapy for IA. The major culprit in the rapid explosion of ARAF in the environment and in patient
lungs appears to be the increasing global use of azole fungicides similar in structure to medical triazoles in
agriculture worldwide, especially in Europe and Asia – these fungicides persist in the soil and water for months,
applying widespread, systematic selection pressure favoring the emergence of ARAF, which in turn spreads quickly
through vegetative growth and abundant dissemination of airborne conidia. ARAF is now responsible for up to 30%
of IA cases in Europe with associated mortality of 70-100%, with steadily rising incidence elsewhere in the world.
Managing patients with ARAF IA is incredibly challenging due to the lack of clinical risk factors, lack of diagnostic
methods that can differentiate ARAF IA from azole-susceptible IA in a timely manner, and the need to employ
antifungals with substantially lower efficacy and greater toxicity than the azole drugs. We have developed methods
of identifying patients with IA via detection of Aspergillus volatile sesquiterpene secondary metabolites in breath,
and of examining in vivo responses to antifungal treatment via serial assessment of these fungal breath metabolites
over the course of antifungal therapy. In contrast to the attenuation of secondary metabolite release in azole-
susceptible A. fumigatus with azole antifungal treatment, these metabolites instead increase in ARAF with azole
exposure. We will test the hypothesis that the sesquiterpene secondary metabolite response to triazole antifungal
therapy is distinct in azole-susceptible and azole-resistant A. fumigatus by (1) comparing the in vitro response of
ARAF (including the most common cyp51A mutations TR34/L98H, TR46/Y121F/T289A, M220, and G54, and ARAF
with phenotypic multi-azole resistance despite wild-type cyp51A) and azole-susceptible A. fumigatus strains to
azole antifungal therapy and (2) comparing the in vivo response of ARAF and azole-susceptible A. fumigatus to
azole antifungal therapy in breath using a neutropenic murine IA model. Ultimately, we expect to delineate
marked differences in the dynamics of volatile sesquiterpene secondary metabolite release in ARAF vs. azole-
susceptible A. fumigatus, both in vitro and in vivo. Successful completion of these aims would set the
groundwork for a novel, rapid breath assay that can distinguish patients with ARAF IA from azole-susceptible
IA, providing an in vivo indicator of imminent therapeutic failure, guiding selection of appropriate antifungal
therapy, and reducing the extremely high morbidity and mortality associated with ARAF IA.
项目摘要/摘要:侵袭性曲霉病 (IA) 是导致发病和死亡的主要原因
免疫功能低下的患者,全世界每年有超过 200,000 例病例。虽然诊断测试取得了进步
强效、毒性较小的三唑类抗真菌药物的开发降低了 IA 相关死亡率
68% 至 25%,耐唑类烟曲霉的发病率和地理分布呈惊人上升趋势
(ARAF)在过去十年中正在稳步抵消这些成果并损害三唑类抗真菌药物的使用
作为 IA 的一线治疗。 ARAF在环境和患者体内迅速爆发的罪魁祸首
肺部似乎越来越多地使用结构与医用三唑类似的唑类杀菌剂
全世界的农业,尤其是欧洲和亚洲——这些杀菌剂在土壤和水中持续数月,
施加广泛的、系统的选择压力,有利于 ARAF 的出现,从而迅速传播
通过营养生长和空气中分生孢子的大量传播。 ARAF 现在负责高达 30%
欧洲 IA 病例的相关死亡率为 70-100%,而世界其他地区的发病率稳步上升。
由于缺乏临床危险因素、缺乏诊断方法,管理 ARAF IA 患者非常具有挑战性。
及时区分 ARAF IA 和唑敏感 IA 的方法,以及需要采用
与唑类药物相比,抗真菌药的功效明显较低,毒性较大。 我们已经开发出方法
通过检测呼吸中的曲霉菌挥发性倍半萜次生代谢物来识别 IA 患者,
以及通过对这些真菌呼吸代谢物的连续评估来检查抗真菌治疗的体内反应
在抗真菌治疗过程中。与唑类中次生代谢物释放的减弱相反
使用唑类抗真菌治疗易感烟曲霉,这些代谢物反而会增加唑类药物的 ARAF
接触。我们将检验以下假设:倍半萜次级代谢产物对三唑类抗真菌药物的反应
通过(1)比较以下药物的体外反应,治疗对唑类敏感和唑类耐药的烟曲霉的治疗是不同的:
ARAF(包括最常见的 cyp51A 突变 TR34/L98H、TR46/Y121F/T289A、M220 和 G54,以及 ARAF
尽管野生型 cyp51A) 和对唑类敏感的烟曲霉菌株仍具有表型多唑类抗性
唑类抗真菌治疗和(2)比较 ARAF 和唑类敏感烟曲霉的体内反应
使用中性粒细胞减少的小鼠 IA 模型进行唑类抗真菌呼吸治疗。最终,我们希望描绘出
ARAF 与唑类中挥发性倍半萜次生代谢物释放动力学存在显着差异
在体外和体内均对烟曲霉敏感。成功完成这些目标将确定
为一种新型快速呼吸检测奠定了基础,该检测可以区分 ARAF IA 患者和唑类敏感患者
IA,提供即将治疗失败的体内指标,指导选择适当的抗真菌药物
治疗,并降低与 ARAF IA 相关的极高发病率和死亡率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sophia Koo其他文献
Sophia Koo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sophia Koo', 18)}}的其他基金
A Novel Device for Rapid and Noninvasive Volatile Metabolite-based Screening and Diagnosis of Multiple Disease States
一种基于挥发性代谢物的快速、无创筛查和诊断多种疾病状态的新型装置
- 批准号:
10663172 - 财政年份:2022
- 资助金额:
$ 25.63万 - 项目类别:
A Novel Device for Rapid and Noninvasive Volatile Metabolite-based Screening and Diagnosis of Multiple Disease States
一种基于挥发性代谢物的快速、无创筛查和诊断多种疾病状态的新型装置
- 批准号:
10426603 - 财政年份:2022
- 资助金额:
$ 25.63万 - 项目类别:
Breath Volatile Metabolites for the Diagnosis of Coccidioidomycosis
呼吸挥发性代谢物用于球孢子菌病的诊断
- 批准号:
10312113 - 财政年份:2020
- 资助金额:
$ 25.63万 - 项目类别:
Rapid, Breath Volatile Metabolite-Based Diagnostic for In Vivo Identification and Antibiotic Resistance Profiling of Bacterial Pathogens in Ventilator-Associated Pneumonia
基于呼吸挥发性代谢物的快速诊断,用于呼吸机相关肺炎细菌病原体的体内鉴定和抗生素耐药性分析
- 批准号:
10630048 - 财政年份:2018
- 资助金额:
$ 25.63万 - 项目类别:
Rapid, Breath Volatile Metabolite-Based Diagnostic for In Vivo Identification and Antibiotic Resistance Profiling of Bacterial Pathogens in Ventilator-Associated Pneumonia
基于呼吸挥发性代谢物的快速诊断,用于呼吸机相关肺炎细菌病原体的体内鉴定和抗生素耐药性分析
- 批准号:
9922858 - 财政年份:2018
- 资助金额:
$ 25.63万 - 项目类别:
Volatile Metabolite-Based Detection of Clostridium difficile Infection
基于挥发性代谢物的艰难梭菌感染检测
- 批准号:
9088345 - 财政年份:2015
- 资助金额:
$ 25.63万 - 项目类别:
Breath Volatile Metabolites for the Diagnosis of Emerging Invasive Mold Infection
呼吸挥发性代谢物用于诊断新发侵袭性霉菌感染
- 批准号:
8875578 - 财政年份:2012
- 资助金额:
$ 25.63万 - 项目类别:
Breath Volatile Metabolites for the Diagnosis of Emerging Invasive Mold Infection
呼吸挥发性代谢物用于诊断新发侵袭性霉菌感染
- 批准号:
8443160 - 财政年份:2012
- 资助金额:
$ 25.63万 - 项目类别:
Breath Volatile Metabolites for the Diagnosis of Emerging Invasive Mold Infection
呼吸挥发性代谢物用于诊断新发侵袭性霉菌感染
- 批准号:
8528464 - 财政年份:2012
- 资助金额:
$ 25.63万 - 项目类别:
Breath Volatile Metabolites for the Diagnosis of Emerging Invasive Mold Infection
呼吸挥发性代谢物用于诊断新发侵袭性霉菌感染
- 批准号:
8699494 - 财政年份:2012
- 资助金额:
$ 25.63万 - 项目类别:
相似海外基金
Is sialic acid recognition receptor a candidate molecule for diagnosis of allergic bronchopulmonary aspergillosis?
唾液酸识别受体是诊断过敏性支气管肺曲霉病的候选分子吗?
- 批准号:
20K07183 - 财政年份:2020
- 资助金额:
$ 25.63万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of new experimental models to understand the genetic basis of allergic bronchopulmonary aspergillosis (ABPA)
开发新的实验模型以了解过敏性支气管肺曲霉病(ABPA)的遗传基础
- 批准号:
NC/P002390/1 - 财政年份:2017
- 资助金额:
$ 25.63万 - 项目类别:
Fellowship
Airway inflamation in allergic bronchopulmonary aspergillosis and the use of Itraconazole
过敏性支气管肺曲霉病的气道炎症和伊曲康唑的使用
- 批准号:
nhmrc : 8201 - 财政年份:2000
- 资助金额:
$ 25.63万 - 项目类别:
NHMRC Postgraduate Scholarships
AEROSOL ANTIGEN CHALLENGE IN ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS
过敏性支气管肺曲霉病中的气溶胶抗原挑战
- 批准号:
4701085 - 财政年份:
- 资助金额:
$ 25.63万 - 项目类别:
AEROSOL ANTIGEN CHALLENGE IN ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS
过敏性支气管肺曲霉病中的气溶胶抗原挑战
- 批准号:
3973552 - 财政年份:
- 资助金额:
$ 25.63万 - 项目类别: